Before the opening bell, Immune Therapeutics, Inc. (OTCQB:
IMUN) announced its entry into a binding letter of intent to acquire Chinese
Chimeric Super Antigen Receptor T cell (CAR-T) cocktail therapy, pending
immuno-oncology patents, manufacturing technology and clinical data regarding
the aforementioned therapies from Super-T Cell Cancer Company (STCC), a
newly-formed corporation. The technology outlined in this letter of intent
could play a key role in IMUN’s ongoing efforts to achieve commercial approval
for its patented immunotherapies, as described by Christopher Pearce, the
company’s chief operating officer, in this morning’s news release:
“This CAR-T cell technology licensing further accelerates
IMUN’s growth in the Immuno-Oncology field as we evaluate paths to
commercialization both in China and other Emerging Markets,” he stated.
CAR-T cell therapy leverages the power of the patient’s own
immune cells to detect and attack cancerous tumors. Data from numerous studies
has suggested that regulatory T cells act as key mediators to the development
of an immunosuppressed microenvironment that would allow tumors to avoid attack
from the immune system and grow unimpeded. Likewise, the CAR-T cocktail therapy
has demonstrated promise in early clinical trials for the treatment of blood,
renal, cervical and hepatic cancers.
“We are very impressed by the quality of the work done by
Professor Shan and his team, and are excited by the safe and efficacious
profile of this novel CAR-T cocktail therapy for cancerous diseases,” Noreen
Griffin, chief executive officer of IMUN, added in this morning’s news release.
“This is the beginning of a long-term strategic partnership between IMUN and
STCC. Together, we will expeditiously continue our quest in developing more affordable,
safer, and more effective cancer immunotherapy programs.”
Upon completion, acquisition of the Super CAR-T cocktail
therapy and its related clinical data is expected to strategically position
IMUN to capitalize on the huge demand for affordable cancer therapies in China.
Industry data suggests that roughly 4.3 million cases of invasive cancers will
be diagnosed in 2016, breaking down to nearly 12,000 new cancer diagnoses with
each passing day. According to a study by leading market researcher Research
and Markets (http://dtn.fm/I24nc), the oncology market in China is expected to
climb to $2.2 billion in 2017, up from just $830 million in 2009.
Despite the rapid growth of the Chinese oncology market,
competition in the cancer therapeutics space has remained highly fragmented.
The top five players in the space, which is currently led by big pharmaceutical
firms of the U.S. and Europe such as Roche/Genentech (OTCQX: RHHBY) and
AstraZeneca (NYSE: AZN), occupy less than 30 percent of total market share. IMUN’s
management team believes that, upon clinical approval of the CAR-T cocktail
therapy, the company could capture as much as five percent of China’s total
market share within the first year.
Learn more by visiting www.immunetherapeutics.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment